New EU commission chief Jean-Claude Juncker has defended his decision to shift the health technology and pharmaceutical policy services back to the more lobby-friendly internal market directorate - a move that has been criticised by MEPs and NGOs.
In the last Barroso commission, the units dealing with medical devices, health technology and cosmetics were part of DG Sanco - the health directorate. Juncker's reorganisation of the commission services has moved these units back to internal ...
Enjoy access to all articles and 25 years of archives, comment and gift articles. Become a member for as low as €1,75 per week.
Already a member? Login